Why is it Necessary to Prioritize the Patients in a Clinical Trial...
pharmatechoutlook

Why is it Necessary to Prioritize the Patients in a Clinical Trial Design?

By Pharma Tech Outlook | Wednesday, November 27, 2019

Clinical trials give their patients access to the best option for treatment in close supervision and supportive setting. Therefore, it is essential to support patients so that they can overcome the barriers while enrolling for a trial.

FREMONT, CA: Enrolment of a patient is essential for the success of the clinical trial, but every time tests are not designed in favor of the cancer patients. Most cancer patients cannot participate in the trails as there are no appropriate trials available for the patient’s cancer type and stage at the center where they are being treated. Moreover, many patients are also ineligible to attend the test due to the exclusion criteria.

Furthermore, there are many patients and healthcare providers who are not aware of clinical trials. Providers are also not well-equipped and trained for the complex biomarker and genetic testing that may be necessary to make sure that the patient is eligible for the study.

The clinicians, researchers, and chief medical officers of The Leukemia & Lymphoma Society (LLS) are trying to find ways to remove the barriers for blood cancer patients and also their caregivers. Here are some of the approaches that the Pharma companies can consider for their clinical trials.

Make Clinical Trial Design Patient-Centered

The LLS teams, along with other researchers, are designing a patient-centered survey to assess the patient preferences for the advantages and risks of acute myeloid leukemia (AML) treatments. The study will permit them to make minute changes, such as minimizing the time in hospital or number of trips back and forth for testing.

Increase the Speed—Deliver More Treatment Options to Patients at Less Time

The LLS team launched a Beat AML Master Clinical Trial, which is a multisite, collaborative trial used for testing multiple targeted therapies simultaneously. Beat AML shows the capability to instantly match patients with the appropriate treatment for their disease subtype by using next-generation genomic technology. The Beat AML was primarily designed to bring more options of treatment for the patients.

Bring Trials to the Communities Where Patients Live

LLS is also continuously working on expanding access to high-quality clinical trials for the patients served by community-based sites of care, mainly rural, minority, and economically disadvantaged blood cancer patients. The patients can participate in the significant cancer trials with the help of their local community center and also lessen traveling to the central hub for treatment.

Weekly Brief